Sugi Predict

Sugi Predict / Compounds / SCHEMBL725160

SCHEMBL725160

SCHEMBL725160

COc1cc(C(=O)c2csc(-c3ccc4[nH]ccc4c3)n2)cc(OC)c1OC

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 1.00
▸ TUBB4A P04350 1/20 0.61
▸ TUBB P07437 1/20 0.61
▸ TUBA3C P0DPH7 1/20 0.61
▸ TUBA1B P68363 1/20 0.61
▸ TUBA4A P68366 1/20 0.61
▸ TUBB4B P68371 1/20 0.61
▸ TUBB3 Q13509 1/20 0.61
▸ TUBB2A Q13885 1/20 0.61
▸ TUBB8 Q3ZCM7 1/20 0.61
▸ TUBA3E Q6PEY2 1/20 0.61
▸ TUBA1A Q71U36 1/20 0.61
▸ TUBA1C Q9BQE3 1/20 0.61
▸ TUBB6 Q9BUF5 1/20 0.61
▸ TUBB2B Q9BVA1 1/20 0.61
▸ TUBB1 Q9H4B7 1/20 0.61
▸ HDAC3 O15379 15/20 0.58
▸ HDAC1 Q13547 15/20 0.58
▸ HDAC7 Q8WUI4 15/20 0.58
▸ HDAC8 Q9BY41 15/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29986893 1.00 EGFR (1.00) EGFRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL4415768 0.92 EGFR (0.85) EGFRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL12245711 0.90 EGFR (0.81) EGFRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL3466531 0.84 EGFR (0.72) EGFRHDAC3HDAC1HDAC7HDAC8
SCHEMBL17732378 0.84 EGFR (0.72) EGFRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL1683629 0.83 EGFR (0.69) EGFRHDAC3HDAC1HDAC7HDAC8
SCHEMBL1683598 0.81 HDAC3 (0.69) EGFRHDAC3HDAC1HDAC7HDAC8
SCHEMBL722466 0.81 HDAC3 (0.69) EGFRHDAC3HDAC1HDAC7HDAC8
SCHEMBL4427854 0.81 EGFR (0.68) EGFRTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31247308 0.81 EGFR (0.68) EGFRTUBB4ATUBBTUBA3CTUBA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2303021-B1 COMPOUNDS FOR THE TREATMENT OF CANCER UNIV TENNESSEE RES FOUND (US) 2018-12-19 — — EP claimed
US-8592465-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-11-26 — — US claimed
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-12-31 — — US claimed
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-06-12 — — US disclosed
US-12187720-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-01-07 — — US disclosed
US-20240180879-A1 METHODS OF TREATING INFLAMMATION VERU INC. (US) 2024-06-06 — — US disclosed
EP-4320151-A1 METHODS OF TREATING INFLAMMATION Veru Inc. (US) 2024-02-14 — — EP disclosed
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — US disclosed
WO-2023196632-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS VERU INC. (US) 2023-10-12 — — WO disclosed
US-20230265081-A1 METHODS OF TREATING CORONAVIRUS VERU INC. (US) 2023-08-24 — — US disclosed
US-11648236-B2 Methods of treating coronavirus VERU INC. (US) 2023-05-16 — — US disclosed
WO-2012027481-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2012-03-01 — — WO disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2011-10-20 — — US disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 — — WO disclosed
WO-2011109059-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2011-09-09 — — WO disclosed
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-12-31 — — US disclosed
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-12-31 — — US disclosed
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187720-B2 Compounds for treatment of cancer KLK3, BRDT, ACP3 EGFR 964/4885TUBB4A 296/4885TUBB 213/4885
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER HCCS, NQO1, CCNY EGFR 263/4885TUBB4A 2060/4885TUBB 2030/4885
US-20240180879-A1 METHODS OF TREATING INFLAMMATION IL1B, PYCARD, TUBB1 EGFR 4826/4885TUBB4A 13/4885TUBB 6/4885
US-20230321045-A1 METHODS OF TREATING INFLUENZA AND POXVIRUS VIRAL INFECTIONS TUBB3, TUBB1, TUBB EGFR 3966/4885TUBB4A 7/4885TUBB 3/4885
US-20230265081-A1 METHODS OF TREATING CORONAVIRUS TUBB3, TUBB1, TUBB EGFR 3883/4885TUBB4A 7/4885TUBB 3/4885
US-20110257196-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 EGFR 964/4885TUBB4A 296/4885TUBB 213/4885
US-11648236-B2 Methods of treating coronavirus TUBB3, TUBB1, TUBB EGFR 3883/4885TUBB4A 7/4885TUBB 3/4885
US-20250188072-A1 COMPOUNDS FOR TREATMENT OF CANCER KLK3, BRDT, ACP3 EGFR 964/4885TUBB4A 296/4885TUBB 213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.